The Alabama Poison Information Center has seen a major increase in calls relating to GLP-1 medications. Ozempic, Mounjaro, ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for Novo Nordisk’s prescriptions, a ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

They are as follows: Losing lean mass - While weight loss is good, GLP-1 drugs cause lean mass muscle ... the drug is going to perform well with its MOA in one or more of these other disorders.

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.